Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCB | P05771 | 5/20 | 1.00 |
| ▸ | PRKCA | P17252 | 5/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 4/20 | 1.00 |
| ▸ | JAK2 | O60674 | 1/20 | 1.00 |
| ▸ | JAK1 | P23458 | 1/20 | 1.00 |
| ▸ | TYK2 | P29597 | 1/20 | 1.00 |
| ▸ | JAK3 | P52333 | 1/20 | 1.00 |
| ▸ | GSK3B | P49841 | 11/20 | 0.76 |
| ▸ | QPCT | Q16769 | 9/20 | 0.76 |
| ▸ | IDH1 | O75874 | 5/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29525929 | 1.00 | PRKCB (1.00) | PRKCBPRKCAPRKCEJAK2JAK1 | |
| SCHEMBL7845205 | 0.97 | PRKCB (0.94) | PRKCBPRKCAPRKCEJAK2JAK1 | |
| SCHEMBL7842255 | 0.94 | PRKCB (0.89) | PRKCBPRKCAPRKCEJAK2JAK1 | |
| SCHEMBL7846087 | 0.94 | JAK2 (0.88) | PRKCBPRKCAPRKCEJAK2JAK1 | |
| SCHEMBL7831887 | 0.94 | JAK2 (0.88) | PRKCBPRKCAPRKCEJAK2JAK1 | |
| SCHEMBL7843484 | 0.94 | JAK2 (0.88) | PRKCBPRKCAPRKCEJAK2JAK1 | |
| SCHEMBL7845267 | 0.91 | JAK2 (0.84) | PRKCBPRKCAPRKCEJAK2JAK1 | |
| SCHEMBL7846144 | 0.91 | JAK2 (0.84) | PRKCBPRKCAPRKCEJAK2JAK1 | |
| SCHEMBL7840928 | 0.90 | PRKCB (0.82) | PRKCBPRKCAPRKCEJAK2JAK1 | |
| SCHEMBL7841423 | 0.89 | PRKCB (0.79) | PRKCBPRKCAPRKCEJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116507347-A | Pharmaceutical composition for treating degenerative brain diseases comprising neural precursor cells derived from pluripotent stem cells | S生物医药公司 | 2023-07-28 | — | — | CN | claimed |
| EP-1120414-A1 | DISUBSTITUTED MALEIMIDE COMPOUNDS AND MEDICINAL UTILIZATION THEREOF | JAPAN TOBACCO INC. (JP) | 2001-08-01 | — | — | EP | claimed |
| US-11827905-B2 | SC-beta cells and compositions and methods for generating the same | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230332107-A1 | CELL THERAPY FOR DIABETES | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-19 | — | — | US | disclosed |
| US-20230332107-A1 | CELL THERAPY FOR DIABETES | VERTEX PHARMACEUTICALS INCORPORATED | 2023-10-19 | — | — | US | disclosed |
| CN-116507347-A | Pharmaceutical composition for treating degenerative brain diseases comprising neural precursor cells derived from pluripotent stem cells | S生物医药公司 | 2023-07-28 | — | — | CN | disclosed |
| US-20230218676-A1 | STEM CELL DERIVED PANCREATIC ISLET DIFFERENTIATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-07-13 | — | — | US | disclosed |
| US-20230146780-A1 | METHODS OF ENHANCING STEM CELL DIFFERENTIATION INTO BETA CELLS | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-11 | — | — | US | disclosed |
| US-20230137854-A1 | METHODS OF ENHANCING STEM CELL DIFFERENTIATION INTO BETA CELLS | VERTEX PHARMA (US) | 2023-05-04 | — | — | US | disclosed |
| US-20220396775-A1 | SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2022-12-15 | — | — | US | disclosed |
| US-20220162562-A1 | SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | HARVARD COLLEGE (US) | 2022-05-26 | — | — | US | disclosed |
| US-20160151379-A1 | COMBINATION THERAPIES FOR MALARIA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-06-02 | — | — | US | disclosed |
| US-20160151380-A1 | THERAPIES FOR DISEASES CAUSED BY ARTHROPOD-BORNE PARASITES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2016-06-02 | — | — | US | disclosed |
| US-20160032249-A1 | COMPOSITIONS AND METHODS FOR PROMOTING THE GENERATION OF ENDOCRINE CELLS | HOWARD HUGHES MEDICAL INSTITUTE | 2016-02-04 | — | — | US | disclosed |
| US-20150240212-A1 | SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | HOWARD HUGHES MEDICAL INSTITUTE | 2015-08-27 | — | — | US | disclosed |
| US-20150218522-A1 | SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | HOWARD HUGHES MEDICAL INSTITUTE | 2015-08-06 | — | — | US | disclosed |
| WO-2015006753-A2 | THERAPIES FOR DISEASES CAUSED BY ARTHROPOD-BORNE PARASITES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-01-15 | — | — | WO | disclosed |
| WO-2015006752-A1 | COMBINATION THERAPIES FOR MALARIA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2015-01-15 | — | — | WO | disclosed |
| WO-2013029043-A1 | SELECTIVE KINASE INHIBITORS | REACTION BIOLOGY CORP. (US) | 2013-02-28 | — | — | WO | disclosed |
| EP-1120414-A1 | DISUBSTITUTED MALEIMIDE COMPOUNDS AND MEDICINAL UTILIZATION THEREOF | JAPAN TOBACCO INC. (JP) | 2001-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218676-A1 | STEM CELL DERIVED PANCREATIC ISLET DIFFERENTIATION | IAPP, PNLIP, ALPG | PRKCB 25/4885PRKCA 53/4885PRKCE 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.